Newsroom

Download PDF BOSTON–(BUSINESS WIRE)–Nov. 10, 2020– AVEO Oncology (Nasdaq: AVEO) todayannounced that Michael Bailey, president and chief executive officer of AVEO, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 11:20 a.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the

Download PDF – U.S. Commercial Launch Preparations Underway Supporting the Tivozanib PDUFA Target Action Date of March 31, 2021 – – Ficlatuzumab Worldwide Rights Regained; Final Results from Open Label Randomized Phase 2 HNSCC Study and Plans for Pivotal Program Expected in the Middle of 2021 – – AV-380 IND Submission Expected by Year-end; Phase 1 Clinical Study Planned for

Download PDF BOSTON & HEMEL HEMPSTEAD, England–(BUSINESS WIRE)–Nov. 5, 2020– AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma today announced that previously reported results from the Phase 1b/2 TiNivo study of oral (PO) tivozanib, AVEO’s next-generation vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) drug candidate, in combination with intravenous (IV) nivolumab (OPDIVO®, Bristol-Myers Squibb), an immune checkpoint,

Download PDF BOSTON–(BUSINESS WIRE)–Oct. 19, 2020– AVEO Oncology (Nasdaq: AVEO) today announced the appointment of David Crist as Vice President of Sales. In this role, Mr. Crist will be responsible for building out AVEO’s sales force in anticipation of the potential approval and launch of tivozanib, the Company’s next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), as a treatment

Download PDF BOSTON–(BUSINESS WIRE)–Sep. 15, 2020– AVEO Oncology (Nasdaq: AVEO) today announced that final overall survival (OS) results from its Phase 3 TIVO-3 study were published in the journal European Urology. TIVO-3 is the Company’s pivotal Phase 3 trial comparing tivozanib, AVEO’s next-generation vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) drug candidate, to sorafenib in third

Download PDF Announces Decision to Fund Clinical Manufacture of Ficlatuzumab for Potential Phase 3 Study and Update to Biodesix Partnership  No Change to AVEO Cash Runway Guidance BOSTON–(BUSINESS WIRE)–Sep. 8, 2020– AVEO Oncology (Nasdaq: AVEO) today announced that it has regained full global rights to ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody which binds to the

Download PDF BOSTON–(BUSINESS WIRE)–Sep. 3, 2020– AVEO Oncology (Nasdaq: AVEO) todayannounced that Michael Bailey, president and chief executive officer of AVEO, will participate in two upcoming virtual investor conferences: Baird 2020 Global Healthcare ConferenceDate: Thursday, September 10Time: 8:30 AM Eastern Time H.C. Wainwright 22nd Annual Global Investment ConferenceDate: Monday, September 14Time: 4:30 PM Eastern Time A live webcast of the events can be accessed by

Download PDF – NDA Filing Accepted by U.S. FDA for Tivozanib as a Treatment of Relapsed or Refractory Renal Cell Carcinoma; Assigned PDUFA Target Action Date of March 31, 2021 – – Preparations Underway to Support Potential Commercial Launch of Tivozanib in the U.S.; New Debt and Equity Financings, Partnership Milestones Potentially Provide for Working Capital into 2022 – –